If Congress were to legalize cannabis at the federal level (i.e., remove it from the Controlled Substances Act and set a national framework), it would resolve today’s clash between state medical programs and federal prohibition. Congressional researchers have repeatedly noted that true “legalization” requires legislative action; administrative rescheduling alone does not fully harmonize federal and state law.
In the nearer term, Washington has already moved toward a different—but consequential—change: reclassifying marijuana from Schedule I to Schedule III. The Justice Department formally proposed this shift in 2024, a historic step that recognizes medical use but stops short of legalization. The rule must clear review and comment before any final action, and—even if finalized—rescheduling would not create nationwide adult-use legality or erase state-by-state rules.
What Would Change for Patients if Federal Policy Shifts?
Lower Prices via Tax Relief
The single most immediate wallet-level effect of rescheduling would be the end of IRS Section 280E for cannabis businesses, allowing normal deductions and lowering effective tax rates. Analysts estimate this could free billions in industry cash flow—savings that could translate to lower retail prices for patients and more product variety. Full legalization would cement (and likely broaden) these benefits across the supply chain.
Clearer Federal Rules—and Likely Stronger Standards
Rescheduling or legalization would pull more cannabis activity under familiar federal regimes. The FDA has long maintained that cannabis- and hemp-derived products fall within its purview, and it has already issued guidance for clinical research and quality considerations. A federal framework would likely ramp up manufacturing standards, labeling uniformity, and adverse-event monitoring—good news for patients who value consistency and safety, though manufacturers would face added compliance obligations.
Interstate Access and Reciprocity
Today, patients who travel often find their medical card has limited or no reciprocity. Legalization with federal interstate commerce could enable multi-state supply chains and, potentially, broader acceptance of patient status across borders. That said, Congress would need to spell out how state medical registries interact across state lines; absent explicit rules, states could still set their own patient eligibility and purchase limits.
Health Care Integration—Slow but Meaningful
Legalization could spur more clinical research and, over time, medical-grade products that move through FDA drug approval channels (think Epidiolex as precedent for CBD). While a wholesale shift to insurance coverage is unlikely overnight, federal legality would remove obstacles that keep many health systems and insurers on the sidelines. Expect incremental adoption: physician education, standardized dosing forms, and outcomes tracking before widespread coverage policies follow.
Veteran Care and the VA
The Department of Veterans Affairs currently allows clinicians to discuss state-legal cannabis but cannot recommend or prescribe it; cardholder status does not jeopardize benefits. Legalization—with or without VA-specific legislation—could open the door to more integrated care pathways for veterans, and bills introduced in 2025 point to growing congressional interest in normalizing veteran access.
Read More: Veterans & Medical Marijuana: The Struggle for VA Support and Recognition
Employment and Drug Testing
Safety-sensitive transportation workers remain subject to DOT drug testing rules regardless of state law. Federal legalization would trigger a complex rewrite of workplace testing standards and impairment policies. Employers may move from THC-presence tests toward impairment-focused approaches, but regulated sectors will likely retain stringent fitness-for-duty requirements. Patients in those roles should expect a slower, more prescriptive transition.
Travel Realities
Until federal law changes, flying with medical cannabis remains largely prohibited under TSA’s federal jurisdiction (with narrow exceptions for FDA-approved cannabinoid drugs or hemp products under 0.3% THC). Legalization would allow TSA policy to modernize and reduce patient risk at airports—though carrying cannabis across international borders would still depend on other nations’ laws.
Will Medical Cards Still Matter?
Yes—but they may evolve. Even with federal legalization, states will likely keep medical programs for minors, higher-THC or specialized formulations, expanded purchase limits, lower taxes, and caregiver models. Cards could become a gateway to clinical-grade products, telehealth renewals, and insurance-supported therapies as evidence grows. Conversely, if rescheduling happens without full legalization, state medical cards will remain essential for lawful access where adult-use isn’t available—and may confer tax or quantity advantages even where it is.
The Big Picture
Federal legalization would simplify life for medical patients: safer supply chains, potentially lower prices, clearer travel rules, and a pathway to mainstream health care. Rescheduling—while meaningful—mainly tackles taxation, research barriers, and federal recognition of medical use. Patients should watch Congress for comprehensive legalization proposals and agencies like FDA and DOT for practical rule changes that determine how care is delivered day to day.
Sources